Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Voyager Therapeutics

- PMLiVE

Novartis’ Fabhalta approved by FDA as first oral monotherapy for rare blood disease PNH

The rare blood disease is estimated to affect only ten to 20 people per million worldwide

- PMLiVE

Novartis gains global rights to Legend’s CAR-T cell therapies in deal worth over $1bn

Novartis can apply its T-Charge platform to the manufacturing process of the therapies

- PMLiVE

Novartis’ Cosentyx receives FDA approval for hidradenitis suppurativa

The decision makes Cosentyx the first biologic treatment approved for HS in nearly a decade

- PMLiVE

Novartis shares positive phase 3 results for atrasentan in rare kidney disease

The company gained access to the candidate after it acquired Chinook Therapeutics

- PMLiVE

Novartis’ Cosentyx recommended by NICE for hidradenitis suppurativa

At least 200,000 people in the UK are affected by the inflammatory skin disease

- PMLiVE

Roche and Monte Rosa enter molecular glue degrader partnership worth over $2bn

The companies will work on therapies for targets in cancer and neurological diseases

- PMLiVE

Roche presents positive results for spinal muscular atrophy treatment Evrysdi in babies

The progressive neuromuscular disease affects approximately one in every 10,000 babies

- PMLiVE

Sandoz separates from Novartis as an independent spin-off company

The split allows Sandoz to strengthen its position in generics and biosimilars

regeneron headquarters

Regeneron and Intellia to develop additional gene editing therapies under expanded collaboration

The companies will develop CRISPR-based therapies for neurological and muscular diseases

- PMLiVE

Novartis sues US government over Medicare drug price negotiation programme

The action comes after the first drugs subject to pricing negotiations were announced

- PMLiVE

Roche’s spinal muscular atrophy therapy Evrysdi approved by EC for newborns

The neuromuscular disease affects approximately one in every 10,000 babies

- PMLiVE

New NHS treatments increase survival rates for babies with spinal muscular atrophy

Around 70 babies are born with the rare muscle-wasting disease each year in the UK

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links